MedTrace Logo

Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus

NCT04153591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2021-12-13

No results posted yet for this study

Summary

To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin.

With limited treatment guideline consensus, minimal evidence to support the use of DOACs for Left Atrial Appendage (LAA) thrombus and Left Ventricular Thrombus (LVT), and a lack of evidence for the use of DOACs in aortic thrombus, further research is warranted to determine the role of DOACs in the treatment of various mural thrombi in comparison to warfarin.

Conditions

  • Acute Myocardial Infarction

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Crystal Brown, PharmD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2020-06-22
Completion
2020-06-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04153591 on ClinicalTrials.gov